Otsuka to acquire Neurovance and rights to ADHD therapy

Japan-based Otsuka Pharmaceutical has acquired US-based (Cambridge, Massachusetts) Neurovance for $100m, plus $150m in additional payments on achievement of precise regulatory and R&D milestones. The acquiree could receive further additional payments linked to its commercial performances. Neurovance focuses on therapeutic solutions to ADHD (Attention-Deficit Hyperactivity Disorder), for which it has developed Centanafadine, currently in advanced-phase clinical trial. According to specialists in the field, ADHD is a therapeutic area worth $13.9bn at present, and growing at a 8.5% CAGR (2014-2024).
(Source: Neurovance)